odiparcil manufacturers
- Odiparcil
-
- $173.00 / 2mg
-
2025-08-21
- CAS:137215-12-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | odiparcil Basic information |
| Product Name: | odiparcil | | Synonyms: | odiparcil;4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one;Odiparcil - SB 424323 | GSK 424323;SB-424323;2H-1-Benzopyran-2-one, 4-methyl-7-[(5-thio-β-D-xylopyranosyl)oxy]-;Odiparcil - SB 424323 | | CAS: | 137215-12-4 | | MF: | C15H16O6S | | MW: | 324.35 | | EINECS: | | | Product Categories: | | | Mol File: | 137215-12-4.mol |  |
| | odiparcil Chemical Properties |
| Boiling point | 567.4±50.0 °C(Predicted) | | density | 1.529±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 12.78±0.70(Predicted) | | color | White to off-white |
| | odiparcil Usage And Synthesis |
| Uses | Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) [1][2]. | | References | [1] Myers AL, et al. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin. J Clin Pharmacol. 2008 Oct;48(10):1158-70 DOI:10.1177/0091270008323751
[2] Levy JH, et al. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010 Sep;113(3):726-45. DOI:10.1097/ALN.0b013e3181ebdb15 |
| | odiparcil Preparation Products And Raw materials |
|